Carbetapentane
As of the edition of 20 October 2026, Carbetapentane is a small molecule: marketed, first approved in 1996 (FR); acts on SIGMAR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Bisolvon Pentoxyverin
- First approved
- 6 May 1996 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Opella Healthcare Switzerland AG; 2 holders in all
- Withdrawn from market
- 1 January 2007 (in some regions)
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Q99720 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2009 to now |